{"url_path":"/sec/elut/8-k/2026-07-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1708527/0001104659-26-085061-index.html","accession_number":"0001104659-26-085061","cik":"0001708527","ticker":"ELUT","issuer_name":"ELUTIA INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1708527/0001104659-26-085061-index.html","primary_entity_key":"0001708527","primary_entity_name":"ELUTIA INC."},"word_count":158,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n**Description**\n\n[10.1*†](tm2620864d1_ex10-1.htm)\n[Asset Purchase Agreement, dated July 16, 2026, by and between Cellution Biologics Inc. and Elutia Inc.](tm2620864d1_ex10-1.htm)\n\n[99.1](tm2620864d1_ex99-1.htm)\n[Press release of Elutia Inc., dated July 16, 2026](tm2620864d1_ex99-1.htm)\n\n104\nCover Page Interactive Data File (formatted as Inline XBRL document)\n\n \n\n*Certain confidential information contained in this Exhibit, marked\nin brackets, has been omitted, because it is both not material and of the type of information that the registrant treats as private or\nconfidential.\n\n \n\n† Schedules have been omitted pursuant to Item 601(a)(5) of\nRegulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**ELUTIA INC.**\n\n \n*(Registrant)*\n\n \n \n\nDate: July 20, 2026\nBy:\n/s/\nMatthew Ferguson\n\n \nMatthew Ferguson\n\n \nChief Financial Officer\n\n \n\n \n\n** **"}